VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Ca

Vertex, Inc. (NASDAQ:VERX) ("Vertex" or the "Company"), the Decision-to-Defense™ glo

Starting with the tax decision, Vertex Sōl connects the work, evidence, and AI that tax professional

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2

The biotech company has grown its annual revenue by more than 600% over the past decade. Kidney dise

Vertex Pharmaceuticals NASDAQ: VRTX outlined updates across its kidney disease pipeline at the Ameri

Shares of Vertex, Inc. (NASDAQ: VERX - Get Free Report) have received an average rating of "Hold" fr

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dan

APPLETON, Wis.--(BUSINESS WIRE)--IGEN, an industry leader in excise tax compliance automation, today

Recognition highlights Vlasic's leadership of Vertex's enterprise AI and data transformation and her

KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX),  the Decision-to

Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormon

KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the

TD Cowen analyst Jared Levine maintains Vertex (NASDAQ:VERX) with a Buy and lowers the price targ

Latigo Biotherapeutics is undervalued below IPO, with onzotrigine showing superior efficacy to Verte

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new inte

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third qu

Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for

KING OF PRUSSIA, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the

Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property

Corient Private Wealth LP purchased a new position in Vertex, Inc. (NASDAQ: VERX) in the second quar

CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editin

Gainers Corvex (NASDAQ:MOVE) stock moved upwards by 44.6% to $15.56 during Tuesday's regular se

DA Davidson analyst Lucky Schreiner maintains Vertex (NASDAQ:VERX) with a Neutral and lowers the

Vertex Inc (NASDAQ:VERX) reported strong Q2 earnings, exceeding analyst estimates. Sales for Q3 also

Stephens & Co. analyst Brett Huff maintains Vertex (NASDAQ:VERX) with a Overweight and lowers

Baird analyst Rob Oliver maintains Vertex (NASDAQ:VERX) with a Outperform and lowers the price ta

Vertex (NASDAQ:VERX) narrows FY2026 sales outlook from $823.500 million-$831.500 million to $825.000

Vertex (NASDAQ:VERX) reported quarterly earnings of $0.20 per share which beat the analyst consensus

Morgan Stanley analyst Chris Quintero downgrades Vertex (NASDAQ:VERX) from Overweight to Equal-We

TD Cowen analyst Jared Levine initiates coverage on Vertex (NASDAQ:VERX) with a Buy rating and an

Citigroup analyst Steven Enders maintains Vertex (NASDAQ:VERX) with a Neutral and raises the pric

Piper Sandler analyst Billy Fitzsimmons maintains Vertex (NASDAQ:VERX) with a Neutral and raises

Vertex (NASDAQ:VERX) affirms FY2026 sales outlook from $823.500 million-$831.500 million to $823.500

Vertex (NASDAQ:VERX) reported quarterly earnings of $0.17 per share which met the analyst consensus

BMO Capital analyst Daniel Jester maintains Vertex (NASDAQ:VERX) with a Market Perform and lowers

Goldman Sachs analyst Adam Hotchkiss maintains Vertex (NASDAQ:VERX) with a Buy and lowers the pri

Citizens analyst Patrick Walravens maintains Vertex (NASDAQ:VERX) with a Market Outperform and lo

Piper Sandler analyst Billy Fitzsimmons maintains Vertex (NASDAQ:VERX) with a Neutral and lowers

Needham analyst Joshua Reilly maintains Vertex (NASDAQ:VERX) with a Buy and lowers the price targ

Vertex (NASDAQ:VERX) reported quarterly earnings of $0.17 per share which beat the analyst consensus

Piper Sandler analyst Hannah Rudoff downgrades Vertex (NASDAQ:VERX) from Overweight to Neutral an

Goldman Sachs sees a familiar pattern returning in 2026: prior-year laggards often beat the S&P

Goldman Sachs analyst Adam Hotchkiss maintains Vertex (NASDAQ:VERX) with a Buy and lowers the pri

Piper Sandler analyst Hannah Rudoff maintains Vertex (NASDAQ:VERX) with a Overweight and lowers t

BMO Capital analyst Daniel Jester maintains Vertex (NASDAQ:VERX) with a Market Perform and lowers